The long-term growth, cost-effectiveness, and glycemic effects of growth hormone therapy on children born small for gestational age over 10 years: a retrospective cohort study
| Autor: | Reem Abdullah Al Khalifah, Amal Alhakami, Yazed AlRuthia, Hadeel Zohair Al Sarraj, Jumana Abulqasim, Ameinah Al-Rasheedi, Akram NurHussen, Ammar Naji |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Pediatric Endocrinology and Metabolism. 35:1357-1368 |
| ISSN: | 2191-0251 0334-018X |
| Popis: | Objectives We aimed to report our 10-year experience of treating short children born small for gestational age (SGA) by comparing the long-term growth, metabolic safety, and cost-effectiveness of recombinant human growth hormone (rhGH) therapy in short children born SGA with those in rhGH-treated children with growth hormone deficiency (GHD) and Turner syndrome. Methods We performed a 10-year retrospective cohort study at King Saud University Medical City. We included children aged 3–16 years who received rhGH for GHD, SGA, or Turner syndrome for >1 year. Results A total of 166 children received rhGH therapy for GHD, 58 for SGA, and 16 for Turner syndrome. During the last study visit, the average height change was 21 cm for GHD children and 14 cm for children born SGA (p-value Conclusions rhGH is effective in height improvement of short children. However, pursuing rhGH treatment for children born SGA requires a shared decision-making approach to balance the modest benefit of final adult height gain with the long-term metabolic effects, considering the acceptable costs on the Saudi healthcare system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|